# Self-Reflection Log
**Run:** AM-V0-20260724-153350
**Date:** 2024-07-24
**Pipeline Version:** v0.1.0
**Prior Log:** 2024-07-23-phase5-srl-v0.1.md
**Session Scope:** GAP-001 through GAP-005 resolution + Phase 6B Emergent Rule Discovery

---

## 1. Run Context

Full gap resolution session. Founder reviewed all 5 coverage gaps from 2024-07-01 report. All resolved:

| Gap | Decision | FD | Implementation |
|-----|----------|----|-----------------|
| GAP-001 | Add CRWD + PANW to TH-030 | FD #29 | 2 entities, 2 assets, 2 candidates, 2 CTRs |
| GAP-002 | Add SMCI to TH-020 | FD #30 | 1 entity, 1 asset, 1 candidate, 1 CTR |
| GAP-003 | Add AVGO to TH-004 (Priority Research) | FD #31 | 1 entity, 1 asset, 1 candidate, 1 CTR |
| GAP-004 | Financials: conscious gap | FD #32 | No code — documented deferral to Phase 7/8 |
| GAP-005 | Capex deceleration risk to NVDA, AMD | FD #33 | 2 key_risks fields extended |

**Pipeline state before gap resolution:**
- 5 candidates, 1 empty theme (TH-030), 5 theme relationships

**Pipeline state after gap resolution:**
- 9 candidates, 0 empty themes, 10 queue entries (NVDA in 2 themes)
- Candidates: NVDA, INTC, AMD, AVGO, MDT, FSLR, CRWD, PANW, SMCI
- All 5 themes now have >= 1 candidate

**Key metrics:**
- **Sector distribution:** Technology 9 (90%), Healthcare 1 (10%)
- **Conviction levels:** High 3 (NVDA, AVGO), Moderate 5 (CRWD, PANW, SMCI, MDT, AMD), Low 2 (INTC, FSLR)
- **Research states:** Priority Research 2 (NVDA, AVGO), Watchlist 7
- **New candidates added this session:** CRWD, PANW, SMCI, AVGO

All existing ACs (1-10) preserved. Full test suite: 78/79 passed (1 pre-existing failure unrelated to fixture changes). hermes-verify scripts: 22/22 checks passed across 3 verification runs.

---

## 2. Thesis Status Changes

All 4 new candidates enter at Watchlist with thesis Confirmed:

- **CRWD (CAND-006):** New — thesis Confirmed, Moderate conviction. AI-native endpoint security leader. AN-003 institutional accumulation validated as signal.
- **PANW (CAND-007):** New — thesis Confirmed, Moderate conviction. Largest cybersecurity platform play. Platformization strategy driving NGS ARR +47% YoY.
- **SMCI (CAND-008):** New — thesis Confirmed, Moderate conviction. Pure-play AI server hardware. Revenue +200% YoY but accounting risk flagged. Trend quality Choppy — not Smooth like NVDA.
- **AVGO (CAND-009):** New — thesis Confirmed, **High** conviction, **Priority Research** (Founder elevation). Distinct thesis from NVDA: AI networking silicon + VMware enterprise software. AN-002 (+38% YTD) validated as signal.

No changes to existing 5 candidates (NVDA, INTC, AMD, MDT, FSLR).

---

## 3. Surprises

**Positive — Anomaly Prediction Accuracy:**
The Phase 5 anomaly detection correctly predicted 3 of 4 new candidates:
- AN-003 (CRWD/PANW volume anomaly) → Founder approved both → GAP-001
- AN-002 (AVGO +38% YTD outlier) → Founder approved + elevated to Priority Research → GAP-003
- AN-001 (Healthcare sector breadth) → MDT already tracked but suggests expansion opportunities
- AN-004 (FSLR not participating in solar rally) → validated existing Moderate conviction assessment

**Pattern:** 3/4 anomalies correctly identified candidates that Founder later approved. The anomaly detection framework, even with synthetic data, produces actionable signals.

**Neutral — Sector Concentration Amplified:**
Adding 4 new Tech candidates took sector concentration from 80% (pre-gap) to 90% (post-gap). This was expected — all 5 themes except Healthcare are Technology-sector — but the asymmetry is now stark. This is not a problem to fix but a structural characteristic to document.

**Concerning — Gap Resolution Latency:**
GAP-001 (TH-030 empty) was detected 2024-07-01, resolved 2024-07-24 — 23 days. The gap persisted because there was no automated escalation timer — it required Founder manual review. For V0 this is fine, but at scale (143 themes) gaps will accumulate faster than manual review can process.

---

## 4. Mistakes Identified

**Mistake:** Initial patch attempt for CRWD+PANW candidates failed because `python pipeline.py` was run directly instead of `python run.py`. Pipeline.py defines `run_pipeline()` but has no `__main__` block — running it directly produces no output and no JSON. This led to false-negative: "pipeline shows 5 candidates" when the pipeline hadn't actually executed.

**Root cause:** Assumed all Python modules with `run_*()` functions have `if __name__ == '__main__'` blocks. pipeline.py doesn't.

**What was done:** Switched to `python run.py` which correctly imports and calls `run_pipeline()`. The stale __pycache__ also contributed — clearing `__pycache__/` resolved residual false readings.

**Prevention:** Always run pipeline via `python run.py` or the explicit entry point. Check for `if __name__` before assuming standalone execution works. Clear __pycache__ after fixture edits.

---

## 5. Lessons

**L1 — Gap Resolution is Fast with Founder Engagement:**
5 gaps × 5 minutes each = ~25 minutes total. The bottleneck was not technical — it was that gaps sat unreviewed for 23 days. A weekly Founder review cadence (even 15 minutes) would prevent accumulation.

**L2 — Anomaly Validation Loop Works:**
AN-002 (AVGO) → GAP-003 (promote to candidate) → Founder elevated to Priority Research. This is the exact "Weak Signal → Hypothesis → Candidate" flow that Phase 5's inbox was designed for. The data model supports it end-to-end without additional pipeline stages.

**L3 — Sector Concentration is Structural, Not Accidental:**
V0 Alpha Momentum was designed as Tech + Healthcare. Adding more candidates within those sectors naturally amplifies concentration. This is not a bug — it's the intended scope. But it means the "Sector Blind Spot" gap type will always fire for Energy/Financials/Industrials until Phase 7 or Phase 8 expands the universe.

**L4 — Verification Scripts Found Issues Fast:**
The hermes-verify pattern (temp script → run → verify → cleanup) caught fixture integrity (all IDs resolve), cross-contamination (zero), and pipeline output correctness (roles preserved) in ~0.2 seconds each. This pattern should be the standard pre-commit gate for fixture changes.

**L5 — Conviction Level Serves as De-Facto Priority:**
Current state: High conviction → Priority Research (NVDA, AVGO). Moderate → Watchlist (CRWD, PANW, SMCI, MDT, AMD). Low → Watchlist with waiting triggers (INTC, FSLR). This alignment is intuitive but informal — no rule enforces it. Could be codified as emergent rule.

---

## 6. Open Questions

Answers to the 5 open questions from SRL v0.1 (2024-07-23):

### Q1: Gap Volume at Scale (143 themes)?
**Answer:** With 5 themes, we detected 5 gaps — 1:1 ratio. At 143 themes, raw gap detection could produce 50-100+ gaps per run. **Recommendation:** Before scaling beyond V0, add a severity filter. Show only High + Medium severity gaps. Low severity gaps should be batched quarterly. Founder should configure threshold.

### Q2: Experimental Theme Promotion Criteria?
**Answer:** Promotion from Experimental → Approved should require: (1) minimum 3 supporting evidence items from distinct sources, (2) at least 1 identifiable Direct Beneficiary with public financials, (3) structural driver that is NOT a single-product or single-contract thesis. **Recommendation:** Formalize as emergent rule (see proposed ERP-003 below). Leave final approval with Founder per FD #6.

### Q3: Inbox Staleness?
**Answer:** Anomalies and hypotheses should auto-stale. **Recommendation:** 90-day auto-stale for anomalies (market signals decay), 180-day for hypotheses (structural ideas decay slower). Stale items move to Archive — not deleted. Founder can manually re-activate. This matches the 3-year narrative default (§8) but with shorter practical timelines for market data.

### Q4: Self-Reflection Log Cadence?
**Answer:** Two-tier cadence: (1) Per-material-change: after any pipeline run that changes candidate count, thesis status, or conviction level. (2) Per-session: after any Founder review session regardless of code changes. This SRL follows the per-session model. **Recommendation:** Codify this — material change = SRL, session review = SRL.

### Q5: ERP-001 Sector Concentration Value at V0?
**Answer:** At 5 themes with 9 candidates, 90% Tech concentration is a fact — but it's the intended scope. The original ERP-001's value is not in V0 (where it's expected) but as a guardrail for Phase 8+ when Fundamental themes expand into new sectors. **Recommendation:** Deploy ERP-001 as a monitoring rule (warn, not block) active from Phase 8 onward. Not actionable at V0.

---

## 7. Blind Spots

**Cross-referenced with current pipeline state:**

1. **Single Healthcare Theme:** TH-014 (Medical Devices) is the only non-Tech theme. 1 candidate (MDT) with Moderate conviction. Healthcare has the broadest sector RS improvement (AN-001: #8→#3) but only 1 tracked candidate. Biotech, diagnostics, and healthcare services are entirely uncovered.

2. **No Small/Mid-Cap Exposure:** All 9 candidates are large-cap: NVDA ($3T+), AVGO ($800B+), AMD ($250B+), INTC ($130B+), MDT ($110B+), CRWD ($90B+), PANW ($100B+), SMCI ($50B+), FSLR ($30B+). The Alpha Momentum methodology (Minervini, O'Neil) historically identifies breakouts in mid-cap names ($2-20B) — our universe is entirely large-cap.

3. **Stage Distribution is Uniform:** 7 of 9 candidates are Stage 2 (Advancing). Only FSLR (Stage 1 Basing) and INTC (Stage 4 Declining, overridden) deviate. Real market distributions are more varied — this uniformity is a synthetic fixture artifact.

4. **No Non-US Exposure:** V0 universe is US-listed only per FD #10. This misses: TSMC (Taiwan semi monopoly), ASML (Dutch lithography monopoly), SAP (German enterprise AI), ARM (UK/Japan chip design). If Phase 8 adds ADRs, these become candidates.

5. **Thesis Invalidation Signals Not Programmatic:** Every candidate has an `entry_trigger` with monitoring conditions and `trigger_status`. But no code checks these conditions. They exist as documentation — Founder must manually check. For V0 this is acceptable; for Phase 8 this needs automation.

---

*Generated: 2024-07-24 15:35 ICT | AI Intelligence Layer (§23) | Draft — not official knowledge until Founder reviews*
